January 2026 in “British Journal of Clinical Pharmacology” In this study, reports from individuals using Serenoa repens indicated a possible post-Serenoa syndrome characterized by persistent sexual and neuropsychiatric symptoms, with causality assessed as 'probable' in 54% of cases, highlighting an underrecognized safety concern that warrants further investigation.
January 2026 in “Pharmaceutical journal/The pharmaceutical journal” The MHRA announced on 11 May 2026 that it will update the product information for finasteride and dutasteride to include more details on potential psychiatric and sexual side effects, following a review of existing evidence.
12 citations
,
May 2017 in “Medicine” This article provides an overview of acne vulgaris, discussing its causes, presentation, and psychosocial impact, but it reports no new research findings or clinical results.
86 citations
,
May 2013 in “American journal of obstetrics and gynecology” This article reviews the care of transgender patients, encompassing diagnosis, treatment options, and challenges in health care access, but does not present new research findings; the authors emphasize the critical role of providers in addressing transgender health needs.
15 citations
,
May 2017 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This article is a letter to the editor about high-dose pulsed corticosteroid therapy combined with methotrexate for severe childhood alopecia areata and provides no new clinical results.